Effect of Subcutaneous Spesolimab on the Prevention of Generalized Pustular Psoriasis Flares Over 48 weeks: Subgroup Analyses from the Effisayil 2 Trial . SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s245, 2023. DOI: 10.25251/skin.7.supp.245. Disponível em: https://skin.dermsquared.com/skin/article/view/2431. Acesso em: 3 jul. 2025.